Literature DB >> 2369713

Prognostic importance of serum transferrin and ferritin in childhood Hodgkin's disease.

H W Hann1, B Lange, M W Stahlhut, K A McGlynn.   

Abstract

The relationship of iron-binding proteins to prognosis was studied in 50 children at the Children's Hospital of Philadelphia, newly diagnosed with Hodgkin's disease (HD). There were five patients with Stage I, 18 with Stage II, 14 with Stage III, and 13 with Stage IV. Initial serum ferritin, transferrin, iron, hemoglobin (Hb), erythrocyte sedimentation rate (ESR), and A or B symptoms were analyzed for their association with progression-free survival (PFS). There was a linear increase of mean and median ferritin levels and a decrease of mean and median transferrin levels with advancing stages. Also, there was a significant inverse correlation between ferritin and transferrin (P less than 0.001). In univariate analyses, high ferritin (greater than 142 ng/ml) (P = 0.02) and low transferrin (less than or equal to 250 mg/dl) (P = 0.008) were significantly associated with poor PFS. Serum iron, Hb, ESR, and A or B symptoms were not associated with PFS. Stepwise proportional hazards regression analysis of all factors showed that transferrin was the only factor significantly associated with PFS. These preliminary results suggest that serum transferrin can also be used as a prognostic factor in addition to serum ferritin and that it may be helpful to assay both serum ferritin and transferrin as prognostic factors in childhood HD. Further testing of large groups of patients is needed to determine whether they are independent of tumor bulk and other established prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369713     DOI: 10.1002/1097-0142(19900715)66:2<313::aid-cncr2820660219>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

Review 2.  Iron and Cancer.

Authors:  Suzy V Torti; David H Manz; Bibbin T Paul; Nicole Blanchette-Farra; Frank M Torti
Journal:  Annu Rev Nutr       Date:  2018-08-21       Impact factor: 11.848

3.  Ferritin as an indicator of disease activity in Hodgkin lymphoma in pediatric patients.

Authors:  Samannay Das; Archana Kashyap; Nidhi Chopra; Kailash C Aggarwal; Aroonima Misra; Amitabh Singh
Journal:  Am J Blood Res       Date:  2022-02-15

Review 4.  Roles of iron in neoplasia. Promotion, prevention, and therapy.

Authors:  E D Weinberg
Journal:  Biol Trace Elem Res       Date:  1992-08       Impact factor: 3.738

5.  Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study.

Authors:  Anna Song; Wankyu Eo; Sehyun Kim; Bumsang Shim; Sookyung Lee
Journal:  BMC Complement Altern Med       Date:  2018-06-07       Impact factor: 3.659

Review 6.  Measurement of iron status in chronic kidney disease.

Authors:  Wesley Hayes
Journal:  Pediatr Nephrol       Date:  2018-04-17       Impact factor: 3.714

Review 7.  Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.

Authors:  Rikki A M Brown; Kirsty L Richardson; Tasnuva D Kabir; Debbie Trinder; Ruth Ganss; Peter J Leedman
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

Review 8.  Iron: An Essential Element of Cancer Metabolism.

Authors:  Myriam Y Hsu; Erica Mina; Antonella Roetto; Paolo E Porporato
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

Review 9.  Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy.

Authors:  Pierre Lelièvre; Lucie Sancey; Jean-Luc Coll; Aurélien Deniaud; Benoit Busser
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.